National Health Council

Dear Research Advocate, Our nation’s research enterprise – and thus our society – has long benefitted mightily from the contributions of foreign-born scientists and engineers. In fact, nearly a third of the STEM workforce is foreign-born . A series of immigration-related actions by the executive branch, some already taken and others considered imminent, imperil academic, industry, and independent research across the country with consequences for our economy, our health, and our well-being. We are hosting an alliance member meeting on the state of play and advocacy opportunities next Monday, June 22 at 2 p.m. ET. Alliance members can register here . On Capitol Hill : Recent reports are that...
“Clinical trial design, cost, regulatory burden and recruitment are some of the challenges associated with clinical research,” said Victor J. Dzau, M.D., president, National Academy of Medicine and Research!America board member. Dzau joined other experts in basic science, clinical and translational research and patient advocacy to explore developments in clinical research during a Research!America Capitol Hill Briefing titled “Innovation Intersection” on June 12, 2017. “We must look at ways to leverage technology and utilize data sharing to make [clinical research] more efficient,” Dzau said. “And, of course, it’s important to shift towards looking at segments of the population, instead of...
Research and development involves collaboration, investments and risk to ensure new treatments benefit patients, according to panelists at a Capitol Hill briefing on February 14 hosted by Research!America and the Congressional R&D Caucus. The briefing “Medical Innovation 101” highlighted various aspects of the research continuum from basic to post-market research. Eleanor Perfetto, Ph.D., MS, of the National Health Council moderated the discussion, which included panelists representing different areas of the medical research continuum: basic science, clinical and translational research, health services research and health economics and the patient community. Keith Yamamoto, Ph.D., Vice...
Is the patient voice adequately represented in the drug development process? The situation has improved but the patient community is not yet recognized as a co-equal in drug development or regulatory review according to Marc Boutin, executive vice president and chief operating officer at the National Health Council , a panelist at a BIO International Convention session on Wednesday. ’€œWe scare you,’€ declares Boutin who says there is an adversarial connection between patients, regulators and industry but the relationship has evolved over the last decade. Patient advocates have developed strategies to amplify their voice and demand access, providing the data and evidence to help transform...

Sidebar Quote

Funding research gives all of us a better chance of living a healthier life.
Pam Hirata, heart disease survivor